Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach

References

• 1 Sheen P-C, Khetarpal VK, Cariola CM, Rowlings CE. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int. J. Pharm. 118(2), 221–227 (1995).
  CASGoogle Scholar
• 2 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1–3), 3–26 (2001).
  Medline CASGoogle Scholar
• 3 Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. 44(1), 235–249 (2000).
  Medline CASGoogle Scholar
• 4 Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413–420 (1995).
  Medline CASGoogle Scholar
• 5 Chiou WL, Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J. Pharm. Sci. 58(12), 1505–1510 (1969).
  Medline CASGoogle Scholar
• 6 Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int. J. Pharm. 212(2), 233–246 (2001).
  Medline CASGoogle Scholar
• 7 Plakkot S, De Matas M, York P, Saunders M, Sulaiman B. Comminution of ibuprofen to produce nano-particles for rapid dissolution. Int. J. Pharm. 415(1-2), 307–314 (2011).
  Medline CASGoogle Scholar
• 8 Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88(10), 1058–1066 (1999).
  Medline CASGoogle Scholar
• 9 Yi T, Wan J, Xu H, Yang X. A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur. J. Pharm. Biopharm. 70(2), 439–444 (2008).
  Medline CASGoogle Scholar
• 10 Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60(9), 1281–1302 (1971).
  Medline CASGoogle Scholar
• 11 Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50(1), 47–60 (2000).
  Medline CASGoogle Scholar
• 12 Mahlin D, Berggren J, Alderborn G, Engstrom S. Moisture-induced surface crystallization of spray-dried amorphous lactose particles studied by atomic force microscopy. J. Pharm. Sci. 93(1), 29–37 (2004).
  Medline CASGoogle Scholar
• 13 Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 12(23–24), 1068–1075 (2007).
  Medline CASGoogle Scholar
• 14 Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine 3(3), 295–309 (2008).
  Medline CASGoogle Scholar
• 15 Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47(1), 3–19 (2001).
  Medline CASGoogle Scholar
• 16 Qi S, Weuts I, De Cort S et al. An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature. J. Pharm. Sci. 99(1), 196–208 (2010).
  Medline CASGoogle Scholar
• 17 Weuts I, Van Dycke F, Voorspoels J et al. Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine. J. Pharm. Sci. 100(1), 260–274 (2011).
  Medline CASGoogle Scholar
• 18 Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86(1), 1–12 (1997).
  Medline CASGoogle Scholar
• 19 Wunderlich B. A classification of molecules, phases, and transitions as recognized by thermal analysis. Thermochimica Acta 340–341, 37–52 (1999).
  CASGoogle Scholar
• 20 Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48(1), 27–42 (2001).
  Medline CASGoogle Scholar
• 21 Bates S, Zografi G, Engers D, Morris K, Crowley K, Newman A. Analysis of amorphous and nanocrystalline solids from their x-ray diffraction patterns. Pharm. Res. 23(10), 2333–2349 (2006).
  Medline CASGoogle Scholar
• 22 Ahlneck C, Zografi G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int. J. Pharm. 62(2–3), 87–95 (1990).
  CASGoogle Scholar
• 23 Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J. Pharm. Sci. 99(9), 3787–3806 (2010).
  Medline CASGoogle Scholar
• 24 Bhardwaj SP, Arora KK, Kwong E, Templeton A, Clas SD, Suryanarayanan R. Correlation between molecular mobility and physical stability of amorphous itraconazole. Mol. Pharm. 10(2), 694–700 (2013).
  Medline CASGoogle Scholar
• 25 Bhardwaj SP, Suryanarayanan R. Molecular mobility as an effective predictor of the physical stability of amorphous trehalose. Mol. Pharm. 9(11), 3209–3217 (2012).
  Medline CASGoogle Scholar
• 26 Bhattacharya S, Suryanarayanan R. Local mobility in amorphous pharmaceuticals – characterization and implications on stability. J. Pharm. Sci. 98(9), 2935–2953 (2009).
  Medline CASGoogle Scholar
• 27 Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J. Pharm. Sci. 97(4), 1329–1349 (2008).
  Medline CASGoogle Scholar
• 28 Graeser KA, Patterson JE, Zeitler JA, Gordon KC, Rades T. Correlating thermodynamic and kinetic parameters with amorphous stability. Eur. J. Pharm. Sci. 37(3–4), 492–498 (2009).
  Medline CASGoogle Scholar
• 29 Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm. Res. 25(4), 969–978 (2008).
  Medline CASGoogle Scholar
• 30 Mahlin D, Bergstrom CA. Early drug development predictions of glass-forming ability and physical stability of drugs. Eur. J. Pharm. Sci. 49(2), 323–332 (2013).
  Medline CASGoogle Scholar
• 31 Van Eerdenbrugh B, Baird JA, Taylor LS. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation – classification and comparison with crystallization tendency from undercooled melts. J. Pharm. Sci. 99(9), 3826–3838 (2010).
  Medline CASGoogle Scholar
• 32 Zhou D, Zhang GG, Law D, Grant DJ, Schmitt EA. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J. Pharm. Sci. 91(8), 1863–1872 (2002).
  Medline CASGoogle Scholar
• 33 Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol. Pharm. 5(6), 927–936 (2008).
  Medline CASGoogle Scholar
• 34 Ohtake S, Shalaev E. Effect of water on the chemical stability of amorphous pharmaceuticals: I. Small molecules. J. Pharm. Sci. 102(4), 1139–1154 (2013).
  Medline CASGoogle Scholar
• 35 Yoshioka S, Aso Y. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J. Pharm. Sci. 96(5), 960–981 (2007).
  Medline CASGoogle Scholar
• 36 Debenedetti PG, Stillinger FH. Supercooled liquids and the glass transition. Nature 410(6825), 259–267 (2001).
  Medline CASGoogle Scholar
• 37 Karmwar P, Boetker JP, Graeser KA, Strachan CJ, Rantanen J, Rades T. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin. Eur. J. Pharm. Sci. 44(3), 341–350 (2011).
  Medline CASGoogle Scholar
• 38 Angell CA. Relaxation in liquids, polymers and plastic crystals – strong/fragile patterns and problems. J. Non-cryst. Solids 131–133(Pt 1), 13–31 (1991).
  CASGoogle Scholar
• 39 Angell CA, Ngai KL, McKenna GB, McMillan PF, Martin SW. Relaxation in glassforming liquids and amorphous solids. J. Appl. Phys. 88(6), 3113–3157 (2000).
  CASGoogle Scholar
• 40 Hancock B, Shamblin S, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12(6), 799–806 (1995).
  Medline CASGoogle Scholar
• 41 Liu J, Rigsbee DR, Stotz C, Pikal MJ. Dynamics of pharmaceutical amorphous solids: the study of enthalpy relaxation by isothermal microcalorimetry. J. Pharm. Sci. 91(8), 1853–1862 (2002).
  Medline CASGoogle Scholar
• 42 Shamblin SL, Hancock BC, Dupuis Y, Pikal MJ. Interpretation of relaxation time constants for amorphous pharmaceutical systems. J. Pharm. Sci. 89(3), 417–427 (2000).
  Medline CASGoogle Scholar
• 43 Ediger MD. Spatially heterogeneous dynamics in supercooled liquids. Annu. Rev. Phys. Chem. 51(1), 99–128 (2000).
  Medline CASGoogle Scholar
• 44 Wojnarowska Z, Grzybowska K, Hawelek L et al. Molecular dynamics, physical stability and solubility advantage from amorphous indapamide drug. Mol. Pharm. 10(10), 3612–3627 (2013).
  Medline CASGoogle Scholar
• 45 Babu NJ, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst. Growth Des. 11(7), 2662–2679 (2011).
  CASGoogle Scholar
• 46 Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17(4), 397–404 (2000).
  Medline CASGoogle Scholar
• 47 Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm. Res. 27(12), 2704–2714 (2010).
  Medline CASGoogle Scholar
• 48 Sekiguchi K, Obi N, Ueda Y. Studies on absorption of eutectic mixture. II. Absrption of fused conglomerates of chloramphenicol and urea in rabbits. Chem. Pharm. Bull. (Tokyo) 12, 134–144 (1964).
  Medline CASGoogle Scholar
• 49 Pham TN, Watson SA, Edwards AJ et al. Analysis of amorphous solid dispersions using 2D solid-state NMR and ¹H T1 relaxation measurements. Mol. Pharm. 7(5), 1667–1691 (2010).
  Medline CASGoogle Scholar
• 50 Qi S, Belton P, Nollenberger K, Clayden N, Reading M, Craig DQ. Characterisation and prediction of phase separation in hot-melt extruded solid dispersions: a thermal, microscopic and NMR relaxometry study. Pharm. Res. 27(9), 1869–1883 (2010).
  Medline CASGoogle Scholar
• 51 Yuan X, Sperger D, Munson EJ. Investigating miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy. Mol. Pharm. 11(1), 329–337 (2013).
  MedlineGoogle Scholar
• 52 Bansal SS, Kaushal AM, Bansal AK. Molecular and thermodynamic aspects of solubility advantage from solid dispersions. Mol. Pharm. 4(5), 794–802 (2007).
  Medline CASGoogle Scholar
• 53 Marsac PJ, Li T, Taylor LS. Estimation of drug–polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm. Res. 26(1), 139–151 (2009).
  Medline CASGoogle Scholar
• 54 Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 23(10), 2417–2426 (2006).
  Medline CASGoogle Scholar
• 55 Paudel A, Worku ZA, Meeus J, Guns S, Van Den Mooter G. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int. J. Pharm. 453(1), 253–284 (2013).
  Medline CASGoogle Scholar
• 56 Qian F, Huang J, Hussain MA. Drug–polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J. Pharm. Sci. 99(7), 2941–2947 (2010).
  Medline CASGoogle Scholar
• 57 Rumondor AC, Ivanisevic I, Bates S, Alonzo DE, Taylor LS. Evaluation of drug–polymer miscibility in amorphous solid dispersion systems. Pharm. Res. 26(11), 2523–2534 (2009).
  Medline CASGoogle Scholar
• 58 Sun DD, Lee PI. Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation. Mol. Pharm. 10(11), 4330–4346 (2013).
  Medline CASGoogle Scholar
• 59 Tao J, Sun Y, Zhang GG, Yu L. Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharm. Res. 26(4), 855–864 (2009).
  Medline CASGoogle Scholar
• 60 Aso Y, Yoshioka S, Kojima S. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. J. Pharm. Sci. 93(2), 384–391 (2004).
  Medline CASGoogle Scholar
• 61 Al-Obaidi H, Lawrence MJ, Shah S, Moghul H, Al-Saden N, Bari F. Effect of drug–polymer interactions on the aqueous solubility of milled solid dispersions. Int. J. Pharm. 446(1-2), 100–105 (2013).
  Medline CASGoogle Scholar
• 62 Caron V, Hu Y, Tajber L et al. Amorphous solid dispersions of sulfonamide/Soluplus^® and sulfonamide/PVP prepared by ball milling. AAPS PharmSciTech 14(1), 464–474 (2013).
  Medline CASGoogle Scholar
• 63 Crowley MM, Zhang F, Repka MA et al. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev. Ind. Pharm. 33(9), 909–926 (2007).
  Medline CASGoogle Scholar
• 64 Repka MA, Battu SK, Upadhye SB et al. Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev. Ind. Pharm. 33(10), 1043–1057 (2007).
  Medline CASGoogle Scholar
• 65 Genina N, Fors D, Vakili H et al. Tailoring controlled-release oral dosage forms by combining inkjet and flexographic printing techniques. Eur. J. Pharm. Sci. 47(3), 615–623 (2012).
  Medline CASGoogle Scholar
• 66 Hsu HY, Toth SJ, Simpson GJ, Taylor LS, Harris MT. Effect of substrates on naproxen-polyvinylpyrrolidone solid dispersions formed via the drop printing technique. J. Pharm. Sci. 102(2), 638–648 (2013).
  Medline CASGoogle Scholar
• 67 Ignatious F, Sun L, Lee CP, Baldoni J. Electrospun nanofibers in oral drug delivery. Pharm. Res. 27(4), 576–588 (2010).
  Medline CASGoogle Scholar
• 68 Kolakovic R, Viitala T, Ihalainen P, Genina N, Peltonen J, Sandler N. Printing technologies in fabrication of drug delivery systems. Expert Opin. Drug Deliv. 10(12), 1711–1723 (2013).
  Medline CASGoogle Scholar
• 69 Ng YC, Yang Z, McAuley WJ, Qi S. Stabilisation of amorphous drugs under high humidity using pharmaceutical thin films. Eur. J. Pharm. Biopharm. 84(3), 555–565 (2013).
  Medline CASGoogle Scholar
• 70 Qi S, Moffat JG, Yang Z. Early stage phase separation in pharmaceutical solid dispersion thin films under high humidity: improved spatial understanding using probe-based thermal and spectroscopic nanocharacterization methods. Mol. Pharm. 10(3), 918–930 (2013).
  Medline CASGoogle Scholar
• 71 Choi YK, Poudel BK, Marasini N et al. Enhanced solubility and oral bioavailability of itraconazole by combining membrane emulsification and spray drying technique. Int. J. Pharm. 434(1-2), 264–271 (2012).
  Medline CASGoogle Scholar
• 72 Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int. J. Pharm. 359(1-2), 211–219 (2008).
  Medline CASGoogle Scholar
• 73 Patel S, Pikal M. Emerging freeze-drying process development and scale-up issues. AAPS PharmSciTech 12(1), 372–378 (2011).
  MedlineGoogle Scholar
• 74 Chang LL, Shepherd D, Sun J, Tang XC, Pikal MJ. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. J. Pharm. Sci. 94(7), 1445–1455 (2005).
  Medline CASGoogle Scholar
• 75 Guo Y, Byrn SR, Zografi G. Effects of lyophilization on the physical characteristics and chemical stability of amorphous quinapril hydrochloride. Pharm. Res. 17(8), 930–935 (2000).
  Medline CASGoogle Scholar
• 76 Sertsou G, Butler J, Scott A, Hempenstall J, Rades T. Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. Int. J. Pharm. 245(1-2), 99–108 (2002).
  Medline CASGoogle Scholar
• 77 Usui F, Maeda K, Kusai A, Ikeda M, Nishimura K, Yamamoto K. Dissolution improvement of RS-8359 by the solid dispersion prepared by the solvent method. Int. J. Pharm. 170(2), 247–256 (1998).
  CASGoogle Scholar
• 78 Dong Z, Chatterji A, Sandhu H, Choi DS, Chokshi H, Shah N. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int. J. Pharm. 355(1–2), 141–149 (2008).
  Medline CASGoogle Scholar
• 79 Janssens S, De Zeure A, Paudel A, Van Humbeeck J, Rombaut P, Van Den Mooter G. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and eudragit e100. Pharm. Res. 27(5), 775–785 (2010).
  Medline CASGoogle Scholar
• 80 Shah S, Maddineni S, Lu J, Repka MA. Melt extrusion with poorly soluble drugs. Int. J. Pharm. 453(1), 233–252 (2013).
  Medline CASGoogle Scholar
• 81 Maniruzzaman M, Rana MM, Boateng JS, Mitchell JC, Douroumis D. Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers. Drug Dev. Ind. Pharm. 39(2), 218–227 (2013).
  Medline CASGoogle Scholar
• 82 Mohammed NN, Majumdar S, Singh A et al. Klucel EF and ELF polymers for immediate-release oral dosage forms prepared by melt extrusion technology. AAPS PharmSciTech 13(4), 1158–1169 (2012).
  Medline CASGoogle Scholar
• 83 De Beer T, Burggraeve A, Fonteyne M, Saerens L, Remon JP, Vervaet C. Near infrared and Raman spectroscopy for the in-process monitoring of pharmaceutical production processes. Int. J. Pharm. 417(1-2), 32–47 (2011).
  Medline CASGoogle Scholar
• 84 Krier F, Mantanus J, Sacre PY et al. PAT tools for the control of co-extrusion implants manufacturing process. Int. J. Pharm. 458(1), 15–24 (2013).
  Medline CASGoogle Scholar
• 85 Saerens L, Dierickx L, Lenain B, Vervaet C, Remon JP, De Beer T. Raman spectroscopy for the in-line polymer-drug quantification and solid state characterization during a pharmaceutical hot-melt extrusion process. Eur. J. Pharm. Biopharm. 77(1), 158–163 (2011).
  Medline CASGoogle Scholar
• 86 Saerens L, Dierickx L, Quinten T et al. In-line NIR spectroscopy for the understanding of polymer–drug interaction during pharmaceutical hot-melt extrusion. Eur. J. Pharm. Biopharm. 81(1), 230–237 (2012).
  Medline CASGoogle Scholar
• 87 Lauer ME, Siam M, Tardio J, Page S, Kindt JH, Grassmann O. Rapid assessment of homogeneity and stability of amorphous solid dispersions by atomic force microscopy – from bench to batch. Pharm. Res. 30(8), 2010–2022 (2013).
  Medline CASGoogle Scholar
• 88 Moffat JG, Qi S, Craig DQ. Spatial characterization of hot melt extruded dispersion systems using thermal atomic force microscopy methods: the effects of processing parameters on phase separation. Pharm. Res. 31(7), 1744–1752 (2014).
  Medline CASGoogle Scholar
• 89 Qi S, Gryczke A, Belton P, Craig DQ. Characterisation of solid dispersions of paracetamol and EUDRAGIT E prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis. Int. J. Pharm. 354(1–2), 158–167 (2008).
  Medline CASGoogle Scholar
• 90 Yang Z, Nollenberger K, Albers J, Craig D, Qi S. Microstructure of an immiscible polymer blend and its stabilization effect on amorphous solid dispersions. Mol. Pharm. 10(7), 2767–2780 (2013).
  Medline CASGoogle Scholar
• 91 Branham ML, Moyo T, Govender T. Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement. Eur. J. Pharm. Biopharm. 80(1), 194–202 (2012).
  Medline CASGoogle Scholar
• 92 Hedoux A, Decroix AA, Guinet Y, Paccou L, Derollez P, Descamps M. Low- and high-frequency Raman investigations on caffeine: polymorphism, disorder and phase transformation. J. Phys. Chem. B 115(19), 5746–5753 (2011).
  Medline CASGoogle Scholar
• 93 Mallick S, Pattnaik S, Swain K et al. Formation of physically stable amorphous phase of ibuprofen by solid state milling with kaolin. Eur. J. Pharm. Biopharm. 68(2), 346–351 (2008).
  Medline CASGoogle Scholar
• 94 Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 63(6), 427–440 (2011).
  Medline CASGoogle Scholar
• 95 Willart JF, Carpentier L, Danede F, Descamps M. Solid-state vitrification of crystalline griseofulvin by mechanical milling. J. Pharm. Sci. 101(4), 1570–1577 (2012).
  Medline CASGoogle Scholar
• 96 Descamps M, Willart JF, Dudognon E, Caron V. Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg. J. Pharm. Sci. 96(5), 1398–1407 (2007).
  Medline CASGoogle Scholar
• 97 Williams GR, Chatterton NP, Nazir T, Yu DG, Zhu LM, Branford-White CJ. Electrospun nanofibers in drug delivery: recent developments and perspectives. Ther. Deliv. 3(4), 515–533 (2012).
  CASGoogle Scholar
• 98 Willart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol. Pharm. 5(6), 905–920 (2008).
  Medline CASGoogle Scholar
• 99 Caron V, Tajber L, Corrigan OI, Healy AM. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Mol. Pharm. 8(2), 532–542 (2011).
  Medline CASGoogle Scholar
• 100 Kawabata Y, Yamamoto K, Debari K, Onoue S, Yamada S. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur J. Pharm. Sci. 39(4), 256–262 (2010).
  Medline CASGoogle Scholar
• 101 Lim RTY, Ng WK, Tan RBH. Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical co-precipitation processing. Powder Technol. 240(0), 79–87 (2013).
  CASGoogle Scholar
• 102 Mahieu A, Willart JF, Dudognon E, Danede F, Descamps M. A new protocol to determine the solubility of drugs into polymer matrixes. Mol. Pharm. 10(2), 560–566 (2013).
  Medline CASGoogle Scholar
• 103 Norrman K, Ghanbari-Siahkali A, Larsen NB. 6 studies of spin-coated polymer films. Ann. Rep. Prog. Chem. Sect. C Phys. Chem. 101, 174–201 (2005).
  CASGoogle Scholar
• 104 Chakraborty S, Liao IC, Adler A, Leong KW. Electrohydrodynamics: a facile technique to fabricate drug delivery systems. Adv. Drug Deliv. Rev. 61(12), 1043–1054 (2009).
  Medline CASGoogle Scholar
• 105 Illangakoon UE, Nazir T, Williams GR, Chatterton NP. Mebeverine-loaded electrospun nanofibers: physicochemical characterization and dissolution studies. J. Pharm. Sci. 103(1), 283–292 (2014).
  Medline CASGoogle Scholar
• 106 Van Eerdenbrugh B, Taylor LS. Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation. Mol. Pharm. 7(4), 1328–1337 (2010).
  Medline CASGoogle Scholar
• 107 Verreck G, Chun I, Peeters J, Rosenblatt J, Brewster ME. Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm. Res. 20(5), 810–817 (2003).
  Medline CASGoogle Scholar
• 108 Verreck G, Chun I, Rosenblatt J et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J. Control. Release 92(3), 349–360 (2003).
  Medline CASGoogle Scholar
• 109 Yu DG, Yang JM, Branford-White C, Lu P, Zhang L, Zhu LM. Third generation solid dispersions of ferulic acid in electrospun composite nanofibers. Int. J. Pharm. 400(1-2), 158–164 (2010).
  Medline CASGoogle Scholar
• 110 Wang L-M, Borick S, Angell CA. An electrospray technique for hyperquenched glass calorimetry studies: propylene glycol and di-n-butyl phthalate. J. Non-cryst. Solids 353(41–43), 3829–3837 (2007).
  CASGoogle Scholar
• 111 Quinten T, Andrews GP, De Beer T et al. Preparation and evaluation of sustained-release matrix tablets based on metoprolol and an acrylic carrier using injection moulding. AAPS PharmSciTech 13(4), 1197–1211 (2012).
  Medline CASGoogle Scholar
• 112 Zema L, Loreti G, Melocchi A, Maroni A, Gazzaniga A. Injection molding and its application to drug delivery. J. Control. Release 159(3), 324–331 (2012).
  Medline CASGoogle Scholar
• 113 Craig DQM. A review of thermal methods used for the analysis of the crystal form, solution thermodynamics and glass transition behaviour of polyethylene glycols. Thermochimica Acta 248, 189–203 (1995).
  CASGoogle Scholar
• 114 Zhu Q, Harris MT, Taylor LS. Modification of crystallization behavior in drug/polyethylene glycol solid dispersions. Mol. Pharm. 9(3), 546–553 (2012).
  Medline CASGoogle Scholar
• 115 Zhu Q, Taylor LS, Harris MT. Evaluation of the microstructure of semicrystalline solid dispersions. Mol. Pharm. 7(4), 1291–1300 (2010).
  Medline CASGoogle Scholar
• 116 Zhu Q, Toth SJ, Simpson GJ, Hsu H-Y, Taylor LS, Harris MT. Crystallization and dissolution behavior of naproxen/polyethylene glycol solid dpspersions. J. Phys. Chem. B 117(5), 1494–1500 (2013).
  Medline CASGoogle Scholar
• 117 Ali W, Williams AC, Rawlinson CF. Stochiometrically governed molecular interactions in drug: poloxamer solid dispersions. Int. J. Pharm. 391(1–2), 162–168 (2010).
  Medline CASGoogle Scholar
• 118 Newa M, Bhandari KH, Oh DH et al. Enhanced dissolution of ibuprofen using solid dispersion with poloxamer 407. Arch. Pharm. Res. 31(11), 1497–1507 (2008).
  Medline CASGoogle Scholar
• 119 Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of vitamin E TPGS in drug delivery. Eur. J. Pharm. Sci. 49(2), 175–186 (2013).
  Medline CASGoogle Scholar
• 120 Shin SC, Kim J. Physicochemical characterization of solid dispersion of furosemide with TPGS. Int. J. Pharm. 251(1–2), 79–84 (2003).
  Medline CASGoogle Scholar
• 121 Damian F, Blaton N, Naesens L et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and gelucire 44/14. Eur. J. Pharm. Sci. 10(4), 311–322 (2000).
  Medline CASGoogle Scholar
• 122 Qi S, Marchaud D, Craig DQ. An investigation into the mechanism of dissolution rate enhancement of poorly water-soluble drugs from spray chilled gelucire 50/13 microspheres. J. Pharm. Sci. 99(1), 262–274 (2010).
  Medline CASGoogle Scholar
• 123 Paudel A, Van Humbeeck J, Van Den Mooter G. Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in poly(vinylpyrrolidone). Mol. Pharm. 7(4), 1133–1148 (2010).
  Medline CASGoogle Scholar
• 124 Janssens S, De Armas HN, Roberts CJ, Van Den Mooter G. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J. Pharm. Sci. 97(6), 2110–2120 (2008).
  Medline CASGoogle Scholar
• 125 Janssens S, Humbeeck JV, Van Den Mooter G. Evaluation of the formulation of solid dispersions by co-spray drying itraconazole with Inutec SP1, a polymeric surfactant, in combination with PVPVA 64. Eur. J. Pharm. Biopharm. 70(2), 500–505 (2008).
  Medline CASGoogle Scholar
• 126 Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion. Int. J. Pharm. 429(1-2), 58–68 (2012).
  Medline CASGoogle Scholar
• 127 Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades T. Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int. J. Pharm. 336(1), 22–34 (2007).
  Medline CASGoogle Scholar
• 128 Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur. J. Pharm. Biopharm. 68(2), 283–288 (2008).
  Medline CASGoogle Scholar
• 129 Corrigan OI. Mechanisms of dissolution of fast release solid dispersions. Drug Dev. Ind. Pharm. 11(2–3), 697–724 (1985).
  CASGoogle Scholar
• 130 Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 231(2), 131–144 (2002).
  Medline CASGoogle Scholar
• 131 Newman A, Knipp G, Zografi G. Assessing the performance of amorphous solid dispersions. J. Pharm. Sci. 101(4), 1355–1377 (2012).
  Medline CASGoogle Scholar
• 132 Jackson CL, McKenna GB. Vitrification and crystallization of organic liquids confined to nanoscale pores. Chem. Mater. 8(8), 2128–2137 (1996).
  CASGoogle Scholar
• 133 Qian KK, Bogner RH. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. J. Pharm. Sci. 101(2), 444–463 (2012).
  Medline CASGoogle Scholar
• 134 Simovic S, Ghouchi-Eskandar N, Sinn AM, Losic D, Prestidge CA. Silica materials in drug delivery applications. Curr. Drug Discov. Technol. 8(3), 269–276 (2011).
  MedlineGoogle Scholar
• 135 Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. Int. J. Pharm. 453(1), 181–197 (2013).
  Medline CASGoogle Scholar
• 136 Azais T, Hartmeyer G, Quignard S, Laurent G, Babonneau F. Solution state NMR techniques applied to solid state samples: characterization of benzoic acid confined in MCM-41. J. Phys. Chem. C 114(19), 8884–8891 (2010).
  CASGoogle Scholar
• 137 Azaïs T, Tourné-Péteilh C, Aussenac F et al. Solid-state NMR study of ibuprofen confined in MCM-41 material. Chem. Mater. 18(26), 6382–6390 (2006).
  Google Scholar
• 138 Brás AR, Merino EG, Neves PD et al. Amorphous ibuprofen confined in nanostructured silica materials: a dynamical approach. J. Phys. Chem. C 115(11), 4616–4623 (2011).
  CASGoogle Scholar
• 139 Hu Y, Wang J, Zhi Z, Jiang T, Wang S. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. J. Colloid. Interface Sci. 363(1), 410–417 (2011).
  Medline CASGoogle Scholar
• 140 Kinnari P, Makila E, Heikkila T, Salonen J, Hirvonen J, Santos HA. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int. J. Pharm. 414(1-2), 148–156 (2011).
  Medline CASGoogle Scholar
• 141 Mellaerts R, Mols R, Jammaer JA et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm. 69(1), 223–230 (2008).
  Medline CASGoogle Scholar
• 142 Shen SC, Ng WK, Chia L, Hu J, Tan RB. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. Int. J. Pharm. 410(1-2), 188–195 (2011).
  Medline CASGoogle Scholar
• 143 Konno T, Kinuno K, Kataoka K. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. I. Effect of vapor pressure of the medicinals on changes in crystalline properties. Chem. Pharm. Bull. (Tokyo) 34(1), 301–307 (1986).
  Medline CASGoogle Scholar
• 144 Qian KK, Bogner RH. Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 1: thermodynamics of spontaneous amorphization. J. Pharm. Sci. 100(7), 2801–2815 (2011).
  Medline CASGoogle Scholar
• 145 Wang Y, Zhao Q, Hu Y et al. Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica. Int. J. Nanomedicine 8, 4015–4031 (2013).
  MedlineGoogle Scholar
• 146 Hailu SA, Bogner RH. Complex effects of drug/silicate ratio, solid-state equivalent pH, and moisture on chemical stability of amorphous quinapril hydrochloride coground with silicates. J. Pharm. Sci. 100(4), 1503–1515 (2011).
  Medline CASGoogle Scholar
• 147 Limnell T, Heikkila T, Santos HA et al. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int. J. Pharm. 416(1), 242–251 (2011).
  Medline CASGoogle Scholar
• 148 Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. Stability of amorphous indomethacin compounded with silica. Int. J. Pharm. 226(1–2), 81–91 (2001).
  Medline CASGoogle Scholar
• 149 Charnay C, Begu S, Tourne-Peteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur. J. Pharm. Biopharm. 57(3), 533–540 (2004).
  Medline CASGoogle Scholar
• 150 Fernandez-Nunez M, Zorrilla D, Montes A, Mosquera MJ. Ibuprofen loading in surfactant-templated silica: role of the solvent according to the polarizable continuum model. J. Phys. Chem. A 113(42), 11367–11375 (2009).
  Medline CASGoogle Scholar
• 151 Bahl D, Bogner RH. Amorphization of indomethacin by co-grinding with neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm. Res. 23(10), 2317–2325 (2006).
  Medline CASGoogle Scholar
• 152 MacLean J, Medina C, Daurio D et al. Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin. J. Pharm. Sci. 100(8), 3332–3344 (2011).
  Medline CASGoogle Scholar
• 153 Vialpando M, Martens JA, Van Den Mooter G. Potential of ordered mesoporous silica for oral delivery of poorly soluble drugs. Ther. Deliv. 2(8), 1079–1091 (2011).
  CASGoogle Scholar
• 154 Beck JS, Vartuli JC, Roth WJ et al. A new family of mesoporous molecular sieves prepared with liquid crystal templates. JACS 114(27), 10834–10843 (1992).
  CASGoogle Scholar
• 155 Chen C-Y, Burkett SL, Li H-X, Davis ME. Studies on mesoporous materials II. Synthesis mechanism of MCM-41. Micropor. Mater. 2(1), 27–34 (1993).
  CASGoogle Scholar
• 156 Kresge CT, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359(6397), 710–712 (1992).
  CASGoogle Scholar
• 157 Sakamoto Y, Kaneda M, Terasaki O et al. Direct imaging of the pores and cages of three-dimensional mesoporous materials. Nature 408(6811), 449–453 (2000).
  Medline CASGoogle Scholar
• 158 Zhao D, Feng J, Huo Q et al. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 Angstrom pores. Science 279(5350), 548–552 (1998).
  Medline CASGoogle Scholar
• 159 Zhao D, Huo Q, Feng J, Chmelka BF, Stucky GD. Nonionic triblock and star diblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrothermally stable, mesoporous silica structures. JACS 120(24), 6024–6036 (1998).
  CASGoogle Scholar
• 160 Wang F, Hui H, Barnes TJ, Barnett C, Prestidge CA. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol. Pharm. 7(1), 227–236 (2009).
  Google Scholar
• 161 Jackson CL, Mckenna GB. The melting behavior of organic materials confined in porous solids. J. Chem. Phys. 93(12), 9002–9011 (1990).
  CASGoogle Scholar
• 162 Vogt FG, Roberts-Skilton K, Kennedy-Gabb SA. A solid-state NMR study of amorphous ezetimibe dispersions in mesoporous silica. Pharm. Res. 30(9), 2315–2331 (2013).
  Medline CASGoogle Scholar
• 163 Miura H, Kanebako M, Shirai H, Nakao H, Inagi T, Terada K. Stability of amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, in silica mesopores and measurement of its molecular mobility by solid-state ¹³C NMR spectroscopy. Int. J. Pharm. 410(1–2), 61–67 (2011).
  Medline CASGoogle Scholar
• 164 Mellaerts R, Aerts CA, Van Humbeeck J, Augustijns P, Van Den Mooter G, Martens JA. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem. Commun. (Camb.) (13), 1375–1377 (2007).
  MedlineGoogle Scholar
• 165 Van Speybroeck M, Mols R, Mellaerts R et al. Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. Eur. J. Pharm. Biopharm. 75(3), 354–365 (2010).
  Medline CASGoogle Scholar
• 166 Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. 59(7), 645–666 (2007).
  Medline CASGoogle Scholar
• 167 Laitinen R, Lobmann K, Strachan CJ, Grohganz H, Rades T. Emerging trends in the stabilization of amorphous drugs. Int. J. Pharm. 453(1), 65–79 (2013).
  Medline CASGoogle Scholar
• 168 Zhang J, Ma PX. Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv. Drug Deliv. Rev. 65(9), 1215–1233 (2013).
  Medline CASGoogle Scholar
• 169 Hoppu P, Jouppila K, Rantanen J, Schantz S, Juppo AM. Characterisation of blends of paracetamol and citric acid. J. Pharm. Pharmacol. 59(3), 373–381 (2007).
  Medline CASGoogle Scholar
• 170 Lu Q, Zografi G. Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP. Pharm. Res. 15(8), 1202–1206 (1998).
  Medline CASGoogle Scholar
• 171 Masuda T, Yoshihashi Y, Yonemochi E, Fujii K, Uekusa H, Terada K. Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir. Int. J. Pharm. 422(1-2), 160–169 (2012).
  Medline CASGoogle Scholar
• 172 Loftsson T, Brewster ME. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. J. Pharm. Sci. 101(9), 3019–3032 (2012).
  Medline CASGoogle Scholar
• 173 Uekama K, Ikegami K, Wang Z, Horiuchi Y, Hirayama F. Inhibitory effect of 2-hydroxypropyl-beta-cyclodextrin on crystal-growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J. Pharm. Pharmacol. 44(2), 73–78 (1992).
  Medline CASGoogle Scholar
• 174 Arima H, Motoyama K, Irie T. Recent findings on safety profiles of cyclodextrins, cyclodextrin conjugates, and polypseudorotaxanes. In: Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine. John Wiley & Sons, Inc., NJ, USA, 91–122 (2011).
  Google Scholar
• 175 Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J. Pharm. Pharmacol. 63(9), 1119–1135 (2011).
  Medline CASGoogle Scholar
• 176 Jun SW, Kim MS, Kim JS et al. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 66(3), 413–421 (2007).
  Medline CASGoogle Scholar
• 177 Lin SY, Hsu CH, Ke WT. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling. Int. J. Pharm. 396(1–2), 83–90 (2010).
  Medline CASGoogle Scholar
• 178 Vega E, Egea MA, Calpena AC, Espina M, Garcia ML. Role of hydroxypropyl-beta-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. Int. J. Nanomedicine 7, 1357–1371 (2012).
  Medline CASGoogle Scholar
• 179 Zheng Y, Chow AH. Production and characterization of a spray-dried hydroxypropyl-beta-cyclodextrin/quercetin complex. Drug Dev. Ind. Pharm. 35(6), 727–734 (2009).
  Medline CASGoogle Scholar
• 180 Brewster ME, Vandecruys R, Verreck G, Peeters J. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie 63(3), 217–220 (2008).
  Medline CASGoogle Scholar
• 181 Taupitz T, Dressman JB, Klein S. In vitro tools for evaluating novel dosage forms of poorly soluble, weakly basic drugs: case example ketoconazole. J. Pharm. Sci. 102(10), 3645–3652 (2013).
  Medline CASGoogle Scholar
• 182 Loh GO, Tan YT, Peh KK. Effect of HPMC concentration on beta-cyclodextrin solubilization of norfloxacin. Carbohydr. Polym. 101, 505–510 (2014).
  Medline CASGoogle Scholar
• 183 Hu Y, Gniado K, Erxleben A, Mcardle P. Mechanochemical reaction of sulfathiazole with carboxylic acids: formation of a cocrystal, a salt, and coamorphous solids. Cryst. Growth Des. 14(2), 803–813 (2013).
  Google Scholar
• 184 Alleso M, Chieng N, Rehder S, Rantanen J, Rades T, Aaltonen J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J. Control. Release 136(1), 45–53 (2009).
  MedlineGoogle Scholar
• 185 Chieng N, Aaltonen J, Saville D, Rades T. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur. J. Pharm. Biopharm. 71(1), 47–54 (2009).
  Medline CASGoogle Scholar
• 186 Chieng N, Rades T, Saville D. Formation and physical stability of the amorphous phase of ranitidine hydrochloride polymorphs prepared by cryo-milling. Eur. J. Pharm. Biopharm. 68(3), 771–780 (2008).
  Medline CASGoogle Scholar
• 187 Löbmann K, Laitinen R, Grohganz H, Gordon KC, Strachan C, Rades T. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol. Pharm. 8(5), 1919–1928 (2011).
  Medline CASGoogle Scholar
• 188 Lobmann K, Strachan C, Grohganz H, Rades T, Korhonen O, Laitinen R. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur. J. Pharm. Biopharm. 81(1), 159–169 (2012).
  Medline CASGoogle Scholar
• 189 Yamamura S, Gotoh H, Sakamoto Y, Momose Y. Physicochemical properties of amorphous precipitates of cimetidine–indomethacin binary system. Eur. J. Pharm. Biopharm. 49(3), 259–265 (2000).
  Medline CASGoogle Scholar
• 190 Yamamura S, Gotoh H, Sakamoto Y, Momose Y. Physicochemical properties of amorphous salt of cimetidine and diflunisal system. Int. J. Pharm. 241(2), 213–221 (2002).
  Medline CASGoogle Scholar
• 191 Blagden N, De Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 59(7), 617–630 (2007).
  Medline CASGoogle Scholar
• 192 Seefeldt K, Miller J, Alvarez-Nunez F, Rodriguez-Hornedo N. Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies. J. Pharm. Sci. 96(5), 1147–1158 (2007).
  Medline CASGoogle Scholar
• 193 Pajula K, Taskinen M, Lehto V-P, Ketolainen J, Korhonen O. Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory−Huggins interaction parameter and phase diagram. Mol. Pharm. 7(3), 795–804 (2010).
  Medline CASGoogle Scholar